RHB-105

RHB-105 is an antibiotics and proton pump inhibitor (PPI) proprietary drug combination for Helicobacter pylori (H. pylori) infection. RHB-105 was acquired from Sydney-based Giaconda [ASX: GIA] in August 2010. RHB-105 is an antibiotics and PPI combination for treatment of H. pylori infections. H. pylori is known to be the major cause of chronic gastritis, peptic ulcer disease, gastric cancer and mucosa associated lymphoid tissue (MALT) lymphoma. Following favorable interim results in a phase IIa study, RedHill announced, in October 2011, of advanced preparations toward a Phase II/III clinical trial with RHB-105, anticipated to commence during the third quarter of 2013.